AI Can Make Prior Authorization Faster. The Consequences Depend on How It Is Used

Prior authorization sits between a clinician's recommendation and a health plan's agreement to cover a service. It is intended to confirm that requested care meets applicable coverage requirements, is medically necessary, and is not duplicative, unsupported, or inappropriate for the circumstances.

That function has legitimate purposes. Health systems and payers must apply benefit rules, manage finite resources, and discourage care that may offer little value. Prior authorization can also create administrative work, delay treatment, and produce decisions that are difficult for patients and clinicians to understand or challenge.

Artificial intelligence and other forms of automation are entering this already complex process. Their effects will depend less on the presence of a particular technology than on the role it is assigned, the rules it applies, the evidence it receives, and the people who retain authority over consequential decisions.

Automation can remove friction. It can also remove opportunities to notice when a rule, record, or recommendation does not fit the patient in front of the system.

Prior authorization is already a decision system

Prior authorization is often described as paperwork. In practice, it is a sequence of administrative and clinical decisions.

A clinician recommends a service. A payer identifies the applicable coverage policy. Documentation is assembled. Clinical and administrative criteria are applied. The request may be approved, denied, returned for more information, or escalated for further review. A patient or provider may then accept the result, resubmit the request, seek peer review, or appeal.

Each stage can produce delay or error. A missing billing code is different from an unresolved clinical question. An incomplete submission is different from a restrictive coverage policy. A software recommendation is different from a final determination issued by an authorized reviewer.

These distinctions matter because the phrase AI prior authorization can refer to several separate functions:

• discovering whether authorization is required;
• retrieving coverage and documentation requirements;
• assembling evidence from the medical record;
• checking whether a submission is complete;
• matching a request to coverage criteria;
• predicting whether a request is likely to be approved;
• recommending approval, denial, or escalation;
• generating a reason for a decision;
• tracking status and supporting an appeal.

The consequences depend on which function is automated and where human judgment remains active.

The human side of prior authorization

Behind every authorization request is a patient waiting for a decision and a clinical team trying to move care forward. Delays can mean postponed treatment, repeated appointments, worsening symptoms, financial uncertainty, and additional work for patients, families, clinicians, and administrative staff. An efficient system should therefore be evaluated not only by how quickly it processes requests, but by how clearly it communicates, how much burden it creates, and what happens to the person receiving care.

Where automation can help

The clearest opportunity is administrative. A well-designed system could identify the correct payer requirements at the point of care, retrieve relevant information from the health record, flag missing documentation, and transmit a complete request electronically. It could also provide status updates without requiring clinic staff to make repeated phone calls or monitor separate portals.

These capabilities would not decide what care a patient should receive. They would reduce the friction surrounding the decision.

Federal policy is moving toward this type of electronic exchange. The Centers for Medicare & Medicaid Services requires affected Medicare Advantage, Medicaid, CHIP, and federally facilitated marketplace plans to meet operational requirements that generally began in 2026 and to implement standardized prior-authorization application programming interfaces beginning in 2027.

The APIs are designed to support coverage-requirement discovery, documentation exchange, request submission, status information, approval information, requests for more information, and specific denial reasons. The principal 2024 rule applies to non-drug items and services.

Related federal health-information-technology requirements support coverage discovery, documentation templates, and electronic authorization submission through standardized implementation specifications.

The practical benefit could be substantial. A clinician may learn during the visit that authorization is required, what evidence the payer expects, and whether the available record is complete. Routine requests that clearly satisfy published criteria could move quickly. Complex cases could be directed to qualified reviewers instead of waiting in the same queue.

Faster decisions can improve access

Speed is clinically relevant. A delayed authorization may postpone imaging, rehabilitation, surgery, transfer to an appropriate care setting, or another needed service. Faster approval can reduce uncertainty for patients, allow clinicians to schedule care sooner, and limit the time spent repeating information already available elsewhere in the system.

Automation may also improve consistency. Coverage criteria can be presented in a standard form, required fields can be checked before submission, and decisions can be timestamped and connected to the policy version applied at the time.

These are meaningful positive consequences: fewer incomplete submissions, fewer avoidable delays, clearer explanations, and faster resolution of routine cases.

But speed measures only how quickly a system reaches an answer. It does not establish whether the answer correctly applies the governing coverage rules or adequately reflects the patient's circumstances.

Faster systems can also scale weak decisions

The same infrastructure that accelerates a valid approval can accelerate an invalid denial.

A software system may faithfully apply a coverage rule that is outdated, too narrow, or inconsistent with governing requirements. It may treat missing structured data as missing clinical evidence. It may fail to account for an unusual presentation or an individual circumstance that is not represented in the data available to it.

Automation can make those problems more consistent without making them more defensible.

In a 2022 review, the U.S. Department of Health and Human Services Office of Inspector General examined a sample of prior-authorization denials issued by 15 large Medicare Advantage organizations using 2019 data. It found that 13 percent of the sampled denials met Medicare coverage rules and likely would have been approved under Original Medicare.

The report identified additional payer criteria and findings of insufficient documentation among the causes. It did not attribute those denials generally to AI.

That limitation is important. Prior-authorization errors can arise from manual review, system configuration, coverage policy, missing information, contractor practices, or combinations of these factors. A high denial rate alone does not prove that an algorithm caused inappropriate decisions.

More recent oversight nevertheless shows why initial review quality matters. In a 2026 report examining June 2024 skilled-nursing-facility requests across 19 Medicare Advantage organizations, the Office of Inspector General found that 12 percent of requests were initially denied. Only 18 percent of those denials were appealed, but 95 percent of appealed denials were overturned in favor of the enrollee.

An appeal can correct a decision. It cannot erase the delay, administrative effort, or unequal capacity required to pursue it.

Human review is necessary, but it is not enough

A common safeguard is to require a person to make or confirm an adverse decision. That is an important control, particularly when medical necessity is disputed. It does not, by itself, establish that the process is reliable.

A human reviewer may receive only a system-generated summary. The reviewer may not have relevant specialty expertise. Time pressure may encourage acceptance of a recommendation without independent examination. A contractor may apply criteria differently from the payer ultimately responsible for the decision.

The meaningful questions are more specific:

• Did the reviewer examine the patient's individual clinical record?
• Was the reviewer qualified to assess the requested service?
• Could the reviewer depart from the software recommendation?
• Was the applicable coverage rule visible?
• Was the reason for the decision recorded?
• Can the decision be audited and appealed later?

California has adopted one explicit state approach. Guidance implementing SB 1120 states that utilization-management tools cannot independently deny, delay, or modify care based on medical necessity and that appropriately qualified licensed professionals must make those determinations. These are state requirements, not a national standard.

CMS has also included clinician review within its Wasteful and Inappropriate Service Reduction model for selected services in Original Medicare. Participating organizations may use enhanced technology, including AI or machine learning, but an appropriately qualified clinician must review a request before a non-affirmation is issued.

These safeguards should be evaluated by their observed performance, not only by their presence in policy.

Electronic infrastructure is advancing while governance remains distributed

The United States is moving toward more standardized electronic prior authorization. Requirements for APIs, specific denial reasons, public metrics, and shorter decision timeframes can make the process more visible.

Rules relevant to AI-assisted prior authorization remain distributed across coverage policy, utilization management, appeals, interoperability, professional review, state insurance law, and civil-rights requirements. They do not yet form one uniform national operating standard for every payer, program, service, and jurisdiction.

Federal civil-rights regulations prohibit covered entities from discriminating through patient-care decision-support tools and require reasonable efforts to identify and mitigate specified discrimination risks associated with their use.

The result is an evolving environment. Electronic exchange is becoming more structured, while expectations for validation, contractor oversight, decision provenance, and public performance reporting remain uneven across programs and jurisdictions.

Positive and negative consequences can exist together

AI-assisted prior authorization may reduce repetitive work, improve the completeness of submissions, shorten routine approval times, and create clearer records of what happened. It may help direct unusual cases to qualified reviewers and identify missing information before a request becomes a denial.

The same systems may also apply defective criteria at scale, obscure the reasoning behind a recommendation, encourage reviewers to defer to software, or shift administrative burden from the payer to clinicians, patients, and appeals teams.

Consistency can be beneficial when the underlying rule is correct. It can be harmful when clinically different cases are treated as though they were identical. Human involvement can provide judgment. It can become ceremonial when the reviewer lacks time, information, expertise, or authority to disagree.

The consequences therefore depend on four design choices:

What is automated, which objective is optimized, who controls the final decision, and whether the result can be explained, appealed, and audited.

What should be measured

A reviewable prior-authorization system should leave a reconstructable decision path. For each consequential determination, it should be possible to identify the service requested, the applicable coverage policy, the version of the criteria used, the clinical evidence submitted, the function performed by automation, the authorized reviewer, the reason for the decision, the appeal route, and the final outcome.

Performance should be evaluated beyond processing time. Useful measures include approval and denial rates by service, decision time, resubmission frequency, appeal frequency, overturn rates, reviewer qualifications, contractor performance, demographic variation, and whether care was delayed or abandoned.

A system may be fast while producing a high rate of reversals. It may be consistent while repeatedly overlooking important individual circumstances. It may reduce payer workload while transferring additional documentation demands to clinical teams.

Without broader outcome information, efficiency is easier to measure than the quality of the decisions being made.

The issue is not automation versus human judgment

Manual prior authorization is not automatically fair, consistent, or clinically correct. Human reviewers can overlook records, misapply criteria, and make different decisions in similar cases.

Technology can help retrieve the correct policy, check that required information is present, present evidence consistently, and preserve an audit trail.

But automation should not erase the distinction between administrative processing, coverage policy, clinical review, and final decision authority.

The strongest use of AI may be to make prior authorization easier to navigate while making consequential decisions easier to examine. That means faster approvals where requirements are clearly satisfied, early identification of missing information, qualified review where judgment is required, and specific explanations when coverage is not granted.

AI can make prior authorization faster. Whether that produces better or worse consequences will depend on how the technology is used, what remains visible, and what happens when a patient or clinician needs the system to reconsider its answer.

Editorial boundary

This article examines general prior-authorization workflows, public regulatory requirements, oversight findings, and technology-governance considerations in the United States. Requirements and practices vary by payer, program, jurisdiction, service, contract, and clinical setting. The article does not determine whether any individual request should be approved or denied.